Merck exec says company is discussing use of COVID antiviral drug in Ebola response

Merck said it is discussing whether its COVID antiviral molnupiravir could be used as an Ebola treatment amid a widening outbreak in the Democratic Republic of Congo that has infected about 1,100 people and caused 42 deaths. The company noted the pill has shown some efficacy in animal studies, but it is not an approved Ebola therapy and no regulatory decision has been made. The news is directionally positive for Merck’s antiviral platform but remains early-stage and unlikely to move the stock materially on its own.

Analysis

This is less about near-term MRK earnings and more about optionality on a platform asset. The market typically underprices when a commercial antiviral gains a geopolitical/public-health wedge case, because the revenue pool is not just acute treatment but stockpiling, procurement, and follow-on protocol adoption if early data are credible. Even a modest ex-U.S. government purchase can create a low-single-digit upside to 2025–26 antiviral revenue expectations, but the bigger value may be in re-rating Merck’s neglected infectious-disease franchise and the perception that its manufacturing/regulatory machine is reusable outside COVID.

The second-order winner is Merck’s vaccine and outbreak-response franchise, not the pill alone. If authorities start treating molnupiravir as a bridge tool for high-risk exposure settings, it can reinforce Ervebo’s strategic relevance and improve Merck’s standing in future public-private procurement cycles. That matters because the competitive moat here is not clinical superiority versus a nonexistent approved standard; it is speed, global supply, and the ability to bundle response solutions, which tends to favor large-cap pharma over smaller biotech in emergency settings.

Main risk: this can fade fast if the outbreak remains localized or if expert consensus pushes back on off-label antiviral deployment absent stronger human evidence. The timing is measured in weeks for headline volatility and months for procurement decisions; if no formal pathway emerges within 1–2 quarters, the market will likely reclassify this as noise. The contrarian read is that the real trade is not a binary Ebola headline squeeze, but a slow-build institutionalization of Merck as an “outbreak infrastructure” company, which could support a multiple premium even if direct sales are immaterial.

Key Decisions for Investors

• Go long MRK on any 1–2 day pullback; target a 3–6 month holding period, with upside driven by procurement/stockpile headlines rather than direct earnings, and risk capped by the fact that the catalyst is optionality, not core revenue dependency.
• Buy MRK Jan-2026 calls / sell shorter-dated calls against them to finance exposure; this captures low-probability but high-convexity headline risk if formal use protocols or stockpiling emerge over the next 1–2 quarters.
• Pair long MRK vs short a basket of smaller infectious-disease names with no emergency-response infrastructure; the thesis is that outbreak monetization accrues to scaled manufacturers and established regulatory channels, not pure-play developers.
• If MRK rallies >5% on headline momentum without formal guidance from health authorities, fade part of the move via short-dated call spreads; the setup is vulnerable to a sharp reset if the story stays anecdotal.
• Monitor for follow-on signals in vaccine procurement or global health partnerships; if those appear, add to MRK and look for a modest multiple expansion rather than just EPS revision.